drugset

drugset / Trial / NCT03939234

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

NCT03939234 ↗

Phase 2 Completed 19 enrolled Lars Møller Pedersen IO Biotech · collab

NaSingle-groupOpen-labelTreatment

Summary

This study is investigating the efficacy of PD-L1 and PD-L2 peptides in untreated CLL patients with unmutated IGHV gene status.

Timeline

Start: 2019-04-26
Primary completion: 2021-03-15
Completion: 2021-03-15

Publications

Klausen U, Grauslund JH, Jorgensen NGD, Ahmad SM, Jonassen M, Weis-Banke SE, Martinenaite E, Pedersen LB, Lisle TL, Gang AO, Enggaard L, Hansen M, Holmstrom MO, Met O, Svane IM, Niemann CU, Pedersen LM, Andersen MH. Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV. Front Oncol. 2022 Nov 22;12:1023015. doi: 10.3389/fonc.2022.1023015. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IO103	Vaccine	—	Subcutaneous
Subject	PD-L2	Unknown	—	Subcutaneous
Background	incomplete Freund's adjuvant	Other / unclassified	—	—

Indications